inside the $14bn Eliquis patent cliff
Eliquis (apixaban) is one of the most commercially consequential loss-of-exclusivity (LOE) events in recent pharmaceutical history, with patent expiries expected this year for Europe and in 2027 for the US and Japan. With global sales of $14.4bn in 2025, the…










